Cognition Therapeutics Inc Cash Flow Conversion Efficiency
Cognition Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Cognition Therapeutics Inc (CGTX) has a cash flow conversion efficiency ratio of -0.155x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.65 Million) by net assets ($36.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cognition Therapeutics Inc (2019–2024)
Cash flow conversion efficiency of Cognition Therapeutics Inc from 2019 to 2024. This chart illustrates how Cognition Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Cognition Therapeutics Inc stock price today for real-time trading data and today's change.
Cognition Therapeutics Inc Cash Flow Conversion Ratio Explained
Cognition Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cognition Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cognition Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Cognition Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anam Electroni
KO:008700
|
-0.077x |
|
C-Tech United
TWO:3625
|
-0.090x |
|
Ilyda SA
AT:ILYDA
|
0.013x |
|
Ravad Ltd
TA:RAVD
|
-0.013x |
|
Sumber Energi Andalan Tbk PT
JK:ITMA
|
-0.002x |
|
Marmota Ltd
AU:MEU
|
-0.010x |
|
TTEC Holdings Inc
NASDAQ:TTEC
|
0.565x |
|
HSS Engineers Bhd
KLSE:0185
|
-0.057x |
Annual Cash Flow Conversion Efficiency for Cognition Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Cognition Therapeutics Inc from 2019 to 2024. Review CGTX FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $18.75 Million | $-28.47 Million | -1.519x | -132.03% |
| 2023-12-31 | $24.47 Million | $-16.02 Million | -0.654x | -42.14% |
| 2022-12-31 | $40.25 Million | $-18.53 Million | -0.460x | -550.21% |
| 2021-12-31 | $51.27 Million | $-3.63 Million | -0.071x | -240.65% |
| 2020-12-31 | $-68.18 Million | $-3.43 Million | 0.050x | -5.05% |
| 2019-12-31 | $-58.42 Million | $-3.10 Million | 0.053x | -- |
About Cognition Therapeutics Inc
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2… Read more